Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
14 hedge funds and large institutions have $7.16M invested in Better Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 9 closing their positions.
30% less funds holding
Funds holding: 20 → 14 (-6)
56% less capital invested
Capital invested by funds: $16.4M → $7.16M (-$9.27M)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$2.06M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$943K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$279K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$120K |
| 5 |
Two Sigma Advisers
New York
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.01M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$700K |
| 3 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$465K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$371K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$329K |
BTTX Hedge Fund Activity: Q1 2022 in Review
14 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q1 2022, worth a combined $7.16M — down 56% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BTTX and 3 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Norges Bank, opening a new position worth an estimated $2.06M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1.01M sold.
- 14 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q1 2022, down from 20 in Q4 2021.
- Funds reported $7.16M of Better Therapeutics, Inc. Common Stock stock for Q1 2022, down 56% quarter-over-quarter.
- 3 funds opened new Better Therapeutics, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of -6 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q1 2022 was Norges Bank, an estimated $2.06M added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q1 2022 was Monashee Investment Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q1 2022.